Deals this week: Corbus Pharmaceuticals Holdings, Dermira, Vycellix

2nd March 2017 (Last Updated March 2nd, 2017 18:30)

US-based clinical-stage pharmaceutical company Corbus Pharmaceuticals Holdings intends to raise up to $27.2m in gross proceeds through the private placement of 3.8 million shares of its common stock.

US-based clinical-stage pharmaceutical company, Corbus Pharmaceuticals Holdings intends to raise up to $27.2m in gross proceeds through the private placement of 3.8 million shares of its common stock.

Priced at $7 a share, the offering will be subscribed to by institutional and accredited investors.

The proceeds will be used for the clinical development of Resunab, a synthetic oral endocannabinoid-mimetic drug being developed to treat chronic inflammatory diseases, and for general corporate purposes.

US-based biopharmaceutical company Dermira intends to raise $168.5m in gross proceeds from an underwritten public offering of its common stock shares.

The company will offer five million shares priced at $33.7 each, while underwriters have a 30-day option to purchase up to 750,000 additional shares.

The company is focused on developing therapies for dermatology diseases.

"US-based biopharmaceutical company Dermira intends to raise $168.5m in gross proceeds from an underwritten public offering of its common stock shares."

Vycellix and Moffitt Cancer Center have signed a research agreement to further validate the former’s novel product candidates, VY-OZ and VY-X, for the potential enhancement of the potency of adoptive cell immunotherapies for cancer.

Vycellix is a US-based biopharmaceutical company, whereas Moffitt Cancer Center is a comprehensive cancer centre based in Sarasota, US.

Italian biotechnology company MolMed and Rocket Pharmaceuticals have entered an agreement to develop gene therapy products for the treatment of Fanconi Anemia.

The lentiviral vectors to be used for the ex-vivo transduction of hematopoietic stem cells will be developed by the former, as part of the agreement. The lentiviral vectors are part of the manufacturing process of the latter Rocket Pharmaceuticals‘ cellular therapy products.

Arrakis Therapeutics has completed a series A venture financing round led by Canaan Partners and participated by Advent Life Sciences, Pfizer, Celgene Corporation, Osage University Partners and Henri Termeer.

The company has raised $38m from the round, with the intention of funding the advancement of its proprietary discovery platforms.